What is ENTX's health score?

Entera Bio Ltd. (ENTX) has a TradeApes health score of 40 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ENTX's estimated fair value?

Based on our 5-year discounted cash flow model, Entera Bio Ltd.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ENTX undervalued or overvalued?

Our model currently rates ENTX as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ENTX... Refresh in a moment for the full analysis.

Entera Bio Ltd. (ENTX)

Healthcare Fair Value Medium weak

Updated: 2026-04-21

TradeApes Score

reduce

Financial Strength

50 Mixed

Operating Trend

20 Stressed

Relative Value

60 Healthy

Capital Allocation

10 Stressed

Risk

55 Mixed

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.